General Information of Drug (ID: DME7OCX)

Drug Name
ENIPORIDE Drug Info
Synonyms
Eniporide; 176644-21-6; N-(diaminomethylene)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; N-Carbamimidoyl-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; EMD-96785; UNII-7IGF9182QU; CHEMBL64360; 7IGF9182QU; Eniporide [INN]; C14H16N4O3S; N-(Diaminomethylene); AC1O5FJV; Eniporide(EMD96785); SCHEMBL6619621; CTK8C4436; UADMBZFZZOBWBB-UHFFFAOYSA-N; MolPort-035-675-643; KS-00000IZ2; EX-A1476; CZC25146; BCP09780; BDBM50058715; ANW-71932; 9260AA; ZINC13555902; AKOS024262733; AKOS016007503; DS-16493; AK-61121; AJ-64172
Indication
Disease Entry ICD 11 Status REF
Cardiac arrhythmias BC9Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
6433092
ChEBI ID
CHEMBL64360
CAS Number
CAS 176644-21-6
TTD Drug ID
DME7OCX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zoniporide hydrochloride DM8L7JD Angina pectoris BA40 Phase 3 [3]
CARIPORIDE DMV2DY3 Angina pectoris BA40 Discontinued in Phase 2 [4]
HOE-694 DML0B97 Heart arrhythmia BC65 Terminated [5]
N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine DMSVQJP Discovery agent N.A. Investigative [5]
N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine DMFG6MU Discovery agent N.A. Investigative [5]
N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine DMGI9EA Discovery agent N.A. Investigative [5]
N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine DMC28SN Discovery agent N.A. Investigative [5]
N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine DM0H8CK Discovery agent N.A. Investigative [5]
N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine DM91463 Discovery agent N.A. Investigative [5]
N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine DMI9GQV Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tenapanor DMCOZJY Irritable bowel syndrome DD91.0 Approved [7]
AVE-0657 DMESMHU Cheyne-stokes respiration MD11.Y Phase 2 [8]
AZD1772//RDX5791 DMX5SG7 Chronic kidney disease GB61 Phase 2 [9]
CARIPORIDE DMV2DY3 Angina pectoris BA40 Discontinued in Phase 2 [2]
HOE-694 DML0B97 Heart arrhythmia BC65 Terminated [5]
N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine DMSVQJP Discovery agent N.A. Investigative [5]
N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine DMFG6MU Discovery agent N.A. Investigative [5]
N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine DMGI9EA Discovery agent N.A. Investigative [5]
N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine DMC28SN Discovery agent N.A. Investigative [5]
N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine DM0H8CK Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/hydrogen exchanger 1 (SLC9A1) TTGSEFH SL9A1_HUMAN Inhibitor [2]
Sodium/hydrogen exchanger 3 (SLC9A3) TTFZVPO SL9A3_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010029)
2 Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47.
3 Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32.
4 Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. Eur J Med Chem. 2009 Sep;44(9):3771-6.
5 (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34.
6 Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8 Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53.
9 RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.